维立志博-B(09887)：LBL-034(GPRC5D/CD3双特异性T-CELL ENGAGER，TCE)获美国FDA授予快速通道资格认定

Core Viewpoint - The company Valiant Pharmaceuticals-B (09887) has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for its drug LBL-034 (GPRC5D/CD3 bispecific antibody) aimed at treating relapsed/refractory multiple myeloma (RRMM) [1] Group 1 - The FDA granted Fast Track Designation to LBL-034 on January 27, 2026 [1] - LBL-034 is specifically developed for the treatment of relapsed/refractory multiple myeloma [1]